Login to Your Account



Bringing In IL13 Phase III Trial Support, NeoPharm Gets $68.4M

By Kim Coghill


Friday, January 23, 2004
NeoPharm Inc. intends to use proceeds from a $68.4 million public offering to advance its cancer agent for malignant glioma. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription